CoreCap Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

CoreCap Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.38K	Hold	23	–	–	﹤0.01%	2603
2026 Q2	$1.32K	Buy	23 +15	+188%	+$822	﹤0.01%	2635
2026 Q1	$452	Hold	8	–	–	﹤0.01%	2667
2025 Q4	$475	Sell	8 -1	-11%	-$54	﹤0.01%	2710
2025 Q3	$487	Hold	9	–	–	﹤0.01%	2571
2025 Q2	$495	Sell	9 -5,262	-100%	-$310K	﹤0.01%	2512
2025 Q1	$373K	Buy	5,271 +5,255	+32,844%	+$354K	0.02%	532
2024 Q4	$1.05K	Buy	16 +7	+78%	+$469	﹤0.01%	2366
2024 Q3	$633	Hold	9	–	–	﹤0.01%	2332
2024 Q2	$741	Hold	9	–	–	﹤0.01%	1414
2024 Q1	$786	Buy	+9	New	+$806	﹤0.01%	2264
2022 Q4	$19.8K	Sell	191 -17,741	-99%	-$1.67M	﹤0.01%	1309
2022 Q3	$1.52M	Buy	17,932 +17,847	+20,996%	+$1.59M	0.13%	145
2022 Q2	$7K	Buy	+85	New	+$6.77K	﹤0.01%	1555
2022 Q1	–	Sell	-100	Closed	-$9K	–	728
2021 Q4	$9K	Buy	+100	New	+$8.25K	﹤0.01%	1572

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Covea Finance Paris, France $3.07B AUM 27.46% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Secure Asset Management Troy, Michigan $753M AUM 20.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

CoreCap Advisors's BMRN Position: Q3 2026 in Review

CoreCap Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 23 shares worth $1.38K. The position accounts for ﹤0.01% of the portfolio, ranked #2603.

CoreCap Advisors first reported a position in BMRN in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.52M in Q3 2022. 86 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

CoreCap Advisors held 23 shares of BioMarin Pharmaceuticals worth $1.38K as of Q3 2026.
CoreCap Advisors left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2603 holding.
CoreCap Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
CoreCap Advisors's BioMarin Pharmaceuticals position peaked at $1.52M in Q3 2022.
86 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.